Rituximab: A very efficient therapy in cold agglutinins and refractory autoimmune haematolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma.

被引:39
作者
Bauduer, F [1 ]
机构
[1] Ctr Hosp Cote Basque, Serv Hematol, F-64100 Bayonne, France
关键词
rituximab; cold agglutinins; autoimmune haemolytic anaemia; non-Hodgkin's lymphoma;
D O I
10.1046/j.1365-2141.2001.02622-3.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1085 / 1086
页数:2
相关论文
共 2 条
[1]   Rituxan in the treatment of cold agglutinin disease [J].
Lee, EJ ;
Kueck, B .
BLOOD, 1998, 92 (09) :3490-3491
[2]   Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].
McLaughlin, P ;
Grillo-López, AJ ;
Link, BK ;
Levy, R ;
Czuczman, MS ;
Williams, ME ;
Heyman, MR ;
Bence-Bruckler, I ;
White, CA ;
Cabanillas, F ;
Jain, V ;
Ho, AD ;
Lister, J ;
Wey, K ;
Shen, D ;
Dallaire, BK .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833